Type 2 Diabetes Market (By Drug Class Insights: Insulin, DPP-4 Inhibitors, GLP-1 Receptor Agonists, SGLT2 Inhibitors, and Others; By Route of Administration Insights: Oral, Subcutaneous, and Intravenous; By Distribution Channel Insights: Retail Pharmacies, Hospital Pharmacies, and Others; By Region: North America, Europe, Asia Pacific, Latin America, and Middle East & Africa) Industry Size, Share, Growth, Trends 2025 to 2034
The global type 2 diabetes market, valued at USD 37.25 billion in 2024, is projected to reach USD 77.18 billion by 2034. Growing prevalence of diabetes, rising adoption of advanced therapies, and improved treatment accessibility are driving its 7.55% CAGR.
| Reports Attributes | Statistics |
| Market Size in 2024 | USD 37.25 Billion |
| Market Size in 2025 | USD 40.09 Billion |
| Market Size in 2031 | USD 62.04 Billion |
| Market Size by 2034 | USD 77.18 Billion |
| CAGR 2025 to 2034 | 7.55% |
| Base Year | 2024 |
| Forecast Period | 2025 to 2034 |
The type 2 diabetes market is expanding at a lucrative pace, driven by the rising urbanization, which has led to major changes in lifestyle patterns, where it has contributing towards unhealthy diets and sedentary lifestyles. Type 2 diabetes T2D is a chronic metabolic disorder where the body doesn’t produce enough insulin or cannot use it effectively, which leads to high glucose levels. The International Diabetes Federation reported that the number of people with diabetes in 2024 was approximately 589 million. Moreover, the WHO also states that more than 95% of people with diabetes have type 2 diabetes, where the incidence among children is reportedly increasing. The aging population in many regions also contributes to the disorder's increasing prevalence and drives significant demand in the healthcare consumables market.
The low- and middle-class economies have a lower understanding of these diseases, which may create barriers for manufacturers and suppliers in these regions. Additionally, a majority of the population does not go for adequate care during the procedures, which may limit the diagnosis rate for such chronic conditions.
The rapid advancements in the healthcare sector are creating several opportunities for healthcare organizations involved in combination therapies, such as SGLT2 inhibitors, which help improve glucose control and address other complications. The rising awareness among individuals is expected to attract more patient volume in the coming years, as they seek personalized healthcare services. As a result, the type 2 diabetes market is more focused on adopting such technologies to attract a huge user base with cost-effective solutions. Use of once-weekly injections and oral delivery is also expected to attract more patients due to their convenience and safety.
Emerging economies like China, India, and Japan are witnessing a rising number of diabetes cases due to urbanization and an aging population. This is attracting several investments from the government and private organizations to expand their healthcare services with digital technologies and advanced solutions. Moreover, the region is expected to offer several opportunities for local manufacturers, helping boost the local economy and businesses.
The rise of artificial intelligence is expected to bring a transformative wave to the type 2 diabetes market, focusing on personalizing treatment plans by analyzing patient data, including activity logs, activity levels, and CGM data. The rise of smart devices is expected to increase the role of these technologies, with the healthcare sector relying on them for data and accuracy. Additionally, machine learning ML algorithms are being implemented at the R&D level to drive further advancements.
| Regions | Shares (%) |
| North America | 40% |
| Asia Pacific | 20% |
| Europe | 30% |
| LAMEA | 10% |
| Segments | Shares (%) |
| Insulin | 30% |
| DPP-4 Inhibitors | 25% |
| GLP-1 Receptor Agonists | 20% |
| SGLT2 Inhibitors | 15% |
| Others | 10% |
| Segments | Shares (%) |
| Oral | 70% |
| Subcutaneous | 25% |
| Intravenous | 5% |
| Segments | Shares (%) |
| Retail Pharmacies | 50% |
| Hospital Pharmacies | 40% |
| Others | 10% |
Published by Rohan Patil
